Update on biomarkers in psoriatic arthritis: A Report from the GRAPPA 2010 Annual Meeting

Journal of Rheumatology

Volumn 39, Issue 2, 2012, Pages 427-430

  Fitzgerald, Oliver ^a   Chandran, Vinod ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Biomarker; Disease activity; Outcome screening; Psoriatic arthritis; Radiographic damage

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CD3 ANTIGEN; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLONY STIMULATING FACTOR 1; DICKKOPF 1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STROMELYSIN; UNCLASSIFIED DRUG;

BLOOD ANALYSIS; BONE RADIOGRAPHY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL ASSESSMENT; MEDICAL RESEARCH; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; OSTEOCLAST; OUTCOME MEASURES IN RHEUMATOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; T LYMPHOCYTE;

ANTIGENS, CD3; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL3; COLLAGEN TYPE II; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 3; OSTEOPROTEGERIN; RECEPTORS, INTERLEUKIN-1 TYPE I; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 84856521465     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111241     Document Type: Conference Paper

References (18)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
2. de Vlam K, Gottlieb AB, FitzGerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008;35:1443-8. (Pubitemid 352000801)
3. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.
4. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: Results of a German national survey. J Eur Acad Dermatol Venereol 2009;23:683-91.
5. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159:322-30. (Pubitemid 352009830)
6. Skoumal M, Haberhauer G, Fink A, Steiner A, Klingler A, Varga F, et al. Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: A marker for unknown peripheral joint involvement? Clin Exp Rheumatol 2008; 26:1087-90.
7. Alenius GM, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha - Markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol 2009;27: 120-3.
8. Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology 2010;49:1399-405.
9. van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: Effects of adalimumab versus placebo. PLoS One 2010;5(9) pii:e12556.
10. Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E, Cozzi L, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-alpha blockade in the knee joint. Arthritis Res Ther 2010;12:R148.
11. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-10.e1-395.
12. Singh TP, Schon MP, Wallbrecht K, Michaelis K, Rinner B, Mayer G, et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010;184:7257-67.
13. Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - A single centre, open-label study. Arthritis Res Ther 2011;13:R7.
14. Reddy SM, Anandarajah AP, Fisher MC, Mease PJ, Greenberg JD, Kremer JM, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol 2010;37:2566-72.
15. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008;67:296-301. (Pubitemid 351281261)
16. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, et al. Circulating mediators of bone remodeling in psoriatic arthritis: Implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010;12:R164.
17. Ng CT, Gibbs A, Murray B, Brady JJ, Bresnihan B, Veale DJ, et al. Bone biomarkers and bone density measurements in patients with inflammatory arthritis prior to and following anti-TNF therapy [abstract]. Arthritis Rheum 2008;58 Suppl:S56.
18. Finzel S, Englbrecht M, Engelke K, Stach C, Schett G. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 2011;70:122-7.